Biomarker Detection News and Research

RSS

New state-of-the-art genomic services facility opening in the UK

Azenta Life Sciences has selected Oxford, UK, a key European life sciences hub, as the location for its next GENEWIZ Multiomics and Synthesis Solutions site.

From Ziath Ltd 8 Dec 2023

New insights into sporadic early-onset Alzheimer's disease

Alzheimer's disease (AD), the most prevalent neurodegenerative disease globally, poses a significant threat to human health.

17 Nov 2023

Highly sensitive blood test shows promise for early detection of common deadly cancers

Most cancers become deadly by keeping a low profile, causing no symptoms until they're too advanced to treat. Ovarian and gastroesophageal cancers are among the most notorious for this sly disease progression, often leading to late-stage diagnoses.

1 Nov 2023

Utilizing Biomarkers in Cancer Prevention, Diagnosis, and Treatment

In this interview, Grace Liu from Sino Biological discusses the crucial role of biomarkers in cancer prevention and diagnosis and how they can help guide treatment decisions.

From Sino Biological Inc. 24 Oct 2023

Blood test for pan-cancer biomarker could revolutionize early cancer detection

Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.

5 Oct 2023

New microneedles could monitor melanoma therapy response

Patients with melanoma, the most concerning form of skin cancer in which pigment-producing cells start to grow out of control, can benefit from existing immunotherapies, but by far not all of them do.

21 Aug 2023

Fully electrical proof-of-concept biosensor for detecting RNA cancer biomarker sequences in solution at the single-molecule level

A group of researchers investigated single-molecule electrical detection of ribonucleic acid (RNA) cancer biomarkers.

3 Aug 2023

Sweat-based wearable technologies as a potential monitoring tool for patients with metabolic syndrome

The opportunities and challenges of sweat-based wearables for monitoring metabolic syndrome.

20 Jul 2023

Quanterix launches LucentAD Biomarker blood test to aid physician diagnosis of Alzheimer’s disease in patients

Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD).

From Quanterix 14 Jul 2023

Hand-held biosensor enables rapid and accurate detection of oral cancer

Oral cancer is the 13th most common type of cancer globally, and oral squamous cell carcinomas (OSCCs) account for more than 90% of oral cancers.

13 Dec 2022

Quanterix’s Simoa® technology drives advances in Alzheimer’s disease research presented at 2022 Clinical Trials On Alzheimer’s Disease (CTAD) conference

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD). The findings were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference held in San Francisco, CA from November 29 to December 2, 2022.

From Quanterix 12 Dec 2022

Can cardiac biomarkers determine COVID-19 prognosis?

Researchers review prognostic cardiac biomarkers in COVID-19 patients.

15 Mar 2022

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

A new study aimed to highlight the different smart and emerging nanomaterials used to detect SARS-CoV-2.

19 Jan 2022

Biomarker predicts severity of SARS-CoV-2 infection in patients

A new study investigates a biomarker to predict the severity of disease in patients infected with SARS-CoV-2.

20 Oct 2021

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks

From Quanterix 9 Aug 2021

High throughput screening for COVID-19 with the VOYAGER pipette

The COVID-19 pandemic has slowed down research in many scientific areas, but for the Jain Lab in the Department of Chemical Engineering at the University of Florida, the pandemic has created an exciting opportunity to repurpose their work.

From INTEGRA Biosciences 24 Mar 2021

New diagnostic platform can rapidly measure COVID-19-related biomarkers

The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute's eRapid technology with the company's proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.

18 Feb 2021

Wyss Institute’s eRapid technology licensed to The iQ Group Global

Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University announced that its eRapid technology has been licensed to The iQ Group Global for COVID-19 diagnostic applications.

30 Nov 2020

Scientists develop a way to accurately detect and monitor common pediatric brain cancer

A team of scientists at Texas A&M University, Baylor College of Medicine and Texas Children's Hospital have developed a way to more accurately both detect and monitor a common type of pediatric brain cancer, setting the stage for giving clinicians a real-time view into how the cancer responds to treatment.

21 Oct 2020

Long-term brain monitoring technologies can benefit epilepsy patients

Today, the way a physician gets an idea of how many seizures a person with epilepsy has had is through the patient's own record of seizure activity in his day-to-day life.

27 Aug 2020